Complete pathologic response after neoadjuvant treatment with vemurafenib for malignant melanoma-Reference-Cited by-同舟云学术

Complete pathologic response after neoadjuvant treatment with vemurafenib for malignant melanoma

Published:2014-02 Issue:2 Volume:70 Page:e39-e41
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Kaidar-Person Orit,Eran Ayelet,Bar-Sela Gil

Publisher

Elsevier BV

Subject

Dermatology

Reference5 articles.

1. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses;Moschos;J Clin Oncol,2006

2. Food and Drug Administration. Vemurafenib. Available from: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm268301.htm. Accessed October 30, 2013.

3. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N Engl J Med,2011

4. Neoadjuvant treatment of a solitary melanoma brain metastasis with vemurafenib;Kolar;J Clin Oncol,2013

5. Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib;Fadaki;BMJ Case Rep,2012

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant BRAF‐targeted therapy in regionally advanced and oligometastatic melanoma;Pigment Cell & Melanoma Research;2019-09-12

2. Vemurafenib y cobimetinib en combinación como neoadyuvancia en el tratamiento del melanoma localmente avanzado irresecable;Piel;2019-01

3. Neutrophil to lymphocyte ratio is an independent predictor of outcome for patients undergoing definitive resection for stage IV melanoma;Journal of Surgical Oncology;2018-09-09

4. 10.5227/skincancer.29.111;Skin Cancer;2015